Benzphetamine Shortage: What Providers and Prescribers Need to Know in 2026

If your patients are reporting difficulty filling Benzphetamine prescriptions, the problem is systemic — not isolated. While Benzphetamine is not formally listed on the FDA Drug Shortage Database, real-world availability has been inconsistent since the broader stimulant supply disruptions that began in 2022.

This briefing covers the current state of Benzphetamine supply, the regulatory and market factors driving the issue, prescribing considerations, and practical tools to help your patients access their medication.

Timeline: How We Got Here

The current availability challenges didn't happen overnight:

• 2022–2023: The DEA's aggregate production quotas for amphetamine-class substances fell short of demand, triggering widespread shortages of Adderall and related medications. As a Schedule III amphetamine derivative, Benzphetamine was caught in the ripple effect.
• 2024: DEA adjusted quotas upward for some stimulants, but Benzphetamine — with its smaller market share — saw minimal benefit. Manufacturing capacity remained constrained by the limited number of producers.
• 2025–2026: Supply has stabilized somewhat but remains unpredictable. The combination of ongoing quota limitations, few manufacturers (Patheon Puerto Rico for Didrex, plus a handful of generic producers), and low pharmacy stocking levels means patients frequently encounter empty shelves.

Prescribing Implications

The supply situation creates several practical considerations for prescribers:

Pharmacy Selection Matters

When writing a Benzphetamine prescription, consider discussing pharmacy options with your patient before they leave the office. Large chain pharmacies often do not stock Benzphetamine routinely. Independent pharmacies tend to have more flexibility in sourcing Schedule III controlled substances from multiple distributors.

Step Therapy and Prior Authorization

Many insurance plans that do cover weight-loss medications require step therapy — typically starting with Phentermine before approving Benzphetamine. Given current availability challenges, documenting prior Phentermine use (or clinical rationale for Benzphetamine) in advance can streamline the authorization process.

Patient Expectations

Setting realistic expectations is important. Patients should understand that:

• Their first pharmacy may not have Benzphetamine in stock
• They may need to check multiple pharmacies or use a search tool like Medfinder for Providers
• A 1–2 week delay is not uncommon if special ordering is required

Current Availability

Benzphetamine is available in a single formulation:

• Benzphetamine Hydrochloride 50 mg oral tablet (scored, peach, round)
• Brand names: Didrex, Regimex
• Generic: Available from multiple manufacturers
• DEA Schedule: III

The typical dosing range is 25 to 50 mg one to three times daily, with a maximum of 150 mg/day. Late afternoon dosing should be avoided due to insomnia risk.

While generic Benzphetamine is technically available, the practical reality is that many pharmacies and distributors do not carry it consistently. This is a supply chain issue, not a manufacturing discontinuation.

Cost and Access Considerations

Cost is a significant barrier for many patients, particularly given the inconsistent insurance coverage of weight-loss medications:

• Cash price: $70 to $625 for 90 tablets, depending on the pharmacy
• With discount cards: $70 to $128 for 90 tablets (SingleCare, GoodRx, and similar programs)
• Generic pricing: As low as $11.24 for 14 tablets at some pharmacies
• Medicare Part D: Generally does not cover weight-loss medications
• Manufacturer assistance: No manufacturer savings or patient assistance program exists for Benzphetamine

Directing patients to discount card programs can reduce out-of-pocket costs significantly. For a patient-facing resource on pricing, consider sharing: How to save money on Benzphetamine.

Tools for Providers

Medfinder for Providers offers real-time pharmacy stock checking that can be integrated into your workflow. Rather than asking patients to call multiple pharmacies, you or your staff can check availability before sending the prescription, ensuring it goes to a pharmacy that actually has the medication in stock.

This is particularly valuable for controlled substances like Benzphetamine, where patients may face additional scrutiny or reluctance from pharmacies when calling to check stock.

Alternative Medications to Consider

When Benzphetamine is unavailable, the following alternatives may be appropriate depending on the clinical situation:

• Phentermine (Adipex-P, Lomaira) — Schedule IV, most widely available, first-line for most patients
• Phendimetrazine (Bontril) — Schedule III, most pharmacologically similar to Benzphetamine
• Diethylpropion (Tenuate) — Schedule IV, may be better tolerated in patients sensitive to stimulant effects
• Orlistat (Xenical, Alli) — Non-controlled, non-stimulant option for patients with cardiovascular contraindications

Final Thoughts

The Benzphetamine supply situation in 2026 remains a challenge driven by structural factors — DEA quotas, limited manufacturing capacity, and low pharmacy stocking levels. These issues are unlikely to resolve quickly.

As prescribers, the most impactful steps you can take are: directing prescriptions to pharmacies confirmed to have stock (using tools like Medfinder), setting patient expectations about potential delays, and being prepared to discuss alternatives when supply is unavailable.

For a patient-facing version of this information, you can share: Benzphetamine shortage update: What patients need to know in 2026.